Sébastien Martel currently serves as Chief Business Officer of Amicus Therapeutics. He brings 30 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease. Mr. Martel joined Amicus in May 2021 to lead the Corporate Strategy and Business Development, Alliance Management, Strategic Planning, and Portfolio Analytics functions. Since then, he has taken over additional responsibilities for the strategic and operational oversight of Technical Operations as of June 2022, of Quality as of October 2023 and of Program Management as of August 2024. Prior to joining Amicus, Mr. Martel spent 12 years at Sanofi, most recently serving as Senior Vice President and Global Head of Rare Diseases, where he led the global rare disease business through multiple global product launches, commercialization, and disease awareness initiatives, in addition to guiding business development and portfolio strategy. Mr. Martel received a Doctor of Pharmacy Degree (PharmD) from the University of Angers, Faculty of Pharmacy, and an M.B.A. from INSEAD. He also holds a Masters in Management for the Pharmaceutical Industry from the Burgundy School of Business.